Huiyu Pharmaceutical announced that Seacross Pharmaceuticals Ltd., a subsidiary of the company, recently received a marketing license approved and issued by the Kosovo Medicines and Health Products Administration, involving concentrated injectable sodium valproate solution, fluvizil injections, cyclophosphamide for injections, levetiracetam concentrated solution for injections, and sodium thiosulfate injections. The company has carried out preliminary preparations for product listing and sales, but due to factors such as product non-uniqueness, competition for similar products, business promotion effects, and sales scale, there is great uncertainty about whether it can generate large revenue in the future; obtaining registration approval does not have a significant impact on the company's business performance in the short term.

Huiyu Pharmaceutical announced that Seacross Pharmaceuticals Ltd., a subsidiary of the company, recently received a marketing license approved and issued by the Kosovo Medicines and Health Products Administration, involving concentrated injectable sodium valproate solution, fluvizil injections, cyclophosphamide for injections, levetiracetam concentrated solution for injections, and sodium thiosulfate injections. The company has carried out preliminary preparations for product listing and sales, but due to factors such as product non-uniqueness, competition for similar products, business promotion effects, and sales scale, there is great uncertainty about whether it can generate large revenue in the future; obtaining registration approval does not have a significant impact on the company's business performance in the short term.